Results 71 to 80 of about 6,146 (182)

Author response: Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

, 2023
Mengyuan Ge, Judith Molina, Jin‐Ju Kim, Shamroop Kumar Mallela, Anis Ahmad, Javier Varona Santos, Hassan Al‐Ali, Alla Mitrofanova, Kumar Sharma, Flavia Fontanesi, Sandra Merscher, Alessia Fornoni   +11 more
openalex   +1 more source

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects [PDF]

, 2023
Edoardo Biancalana, Chiara Rossi, Francesco Raggi, Mariarosaria Distaso, Domenico Tricò, Simona Baldi, Ele Ferrannini, Anna Solini   +7 more
openalex   +1 more source

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source

Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia

Frontiers in Pharmacology
Background and aimsRecent studies suggest that empagliflozin reduces total and cardiovascular mortality in both diabetic and nondiabetic subjects. Although the exact mechanism is unclear, it is understood to positively affect myocardial energetics ...
Denisa Miklankova, Denisa Miklankova, Irena Markova, Martina Hüttl, Hana Malinska   +4 more
doaj   +1 more source

Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice [PDF]

, 2023
Ryo Kawakami, Hiroki Matsui, Miki Matsui, Tatsuya Iso, Tomoyuki Yokoyama, Hideki Ishii, Masahiko Kurabayashi   +6 more
openalex   +1 more source

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho   +15 more
wiley   +1 more source

Role of Empagliflozin in heart failure with severe aortic stenosis before valve replacement: EASTER-HF study

Indian Heart Journal
We evaluated empagliflozin in severe DAS patients with HF before AVR. HF patients with LVEF 30–80 % and NYHA functional class II-IV symptoms got empagliflozin 10 mg or not within 6 months before AVR, along with SOC. Adding empagliflozin to the SOC before
Pankaj Jariwala, Gururaj Pramod Kulkarni, Arshad Punjani, Harikishan Boorugu, Dilip Gude   +4 more
doaj   +1 more source

Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The extent to which the cardiovascular benefits of sodium–glucose co‐transporter 2 inhibitors (SGLT‐2is) and glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) differ by sex remains unclear. This systematic meta‐analysis aimed to investigate sex differences in trial representation and the cardiovascular and kidney efficacy of SGLT‐2is ...
Magdaline Zawadka, Erwin Taguiam, Mê‐Linh Lê, Rohan Sanjanwala, Shuangbo Liu, Ashish H. Shah, Setor K. Kunutsor   +6 more
wiley   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source